Brief: Lilly's Jaypirca (Pirtobrutinib) Significantly Reduced The Risk Of Disease Progression Or Death By 45% When Added To A Venetoclax Time-Limited Regimen In People With Previously Treated Cll/Sll
14/06/2026 08:18
BRIEF-Lilly's Jaypirca (Pirtobrutinib) Significantly Reduced The Risk Of Disease Progression Or Death By 45% When Added To A Venetoclax Time-Limited Regimen In People With Previously Treated Cll/Sll June 14 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PEOPLE WITH PREVIOUSLY TREATED CLL/SLL
ELI LILLY - STUDY MEETS PRIMARY ENDPOINT WITH 45% RISK REDUCTION (HR=0.55; P=0)
Source text: ID:nPnX9TkBa
Further company coverage: LLY.N
((Reuters.briefs@thomsonreuters.com;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)